Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan

One-year clinical outcomes (RECONFIRM-2)

Yoshiya Tanaka, Tsutomu Takeuchi, Eisuke Inoue, Kazuyoshi Saito, Naoya Sekiguchi, Eri Sato, Masao Nawata, Hideto Kameda, Shigeru Iwata, Kouichi Amano, Hisashi Yamanaka

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Biologics targeting TNF have brought about a paradigm shift in the treatment of rheumatoid arthritis (RA) and infliximab, anti-TNF-α chimeric monoclonal antibody, was marketed in 2003 in Japan. We previously reported on the RECONFIRM study, a retrospective clinical study on the efficacy of infliximab therapy in a RA management group in Japan, where we evaluated the clinical response after 22 weeks of the therapy in 258 patients. The study reported here was aimed at reconfirming the clinical efficacy of the infliximab therapy and demographic factors related to the efficacy over a 54-week study period in 410 RA patients in the same study group. Infliximab was infused according to the domestically approved method, and the clinical response was evaluated following 54 weeks of infliximab therapy using the European League Against Rheumatism (EULAR) response criteria. Disease activity was assessed by DAS28-CRP (Disease Activity Score including a 28-joint count/C-reactive protein). Infliximab was discontinued in 24.4% of the 410 patients at 54 weeks and 9.3% and 8.1% discontinued the therapy due to adverse events and inefficiency, respectively. Average DAS28-CRP decreased from 5.5 at week 0 to 3.1 at week 54 after the therapy. Patients in remission and those showing low-, moderate-, and high-disease activity changed from 0.0, 1.0, 9.0 and 90.0%, respectively, at the start of the study to 27.6, 11.7, 34.4 and 26.3%, respectively, at week 54. Younger age, RF-negativity and low scores of DAS28-CRP showed significant correlations with remission at week 54. EULAR response criteria - good, moderate, and no response to infliximab - were 37.0, 41.7 and 21.2%, respectively. In conclusion, we reconfirmed the clinical efficacy of infliximab and demographic factors related to the efficacy over a 54-week study period in 410 Japanese patients with RA using DAS28-CRP and EULAR response criteria.

Original languageEnglish
Pages (from-to)146-152
Number of pages7
JournalModern Rheumatology
Volume18
Issue number2
DOIs
Publication statusPublished - 2008 Apr
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Japan
Retrospective Studies
C-Reactive Protein
Joints
Therapeutics
Rheumatic Diseases
Demography
Clinical Studies
Infliximab
Biological Products
Monoclonal Antibodies

Keywords

  • EULAR response
  • Infliximab
  • Retrospective study
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan : One-year clinical outcomes (RECONFIRM-2). / Tanaka, Yoshiya; Takeuchi, Tsutomu; Inoue, Eisuke; Saito, Kazuyoshi; Sekiguchi, Naoya; Sato, Eri; Nawata, Masao; Kameda, Hideto; Iwata, Shigeru; Amano, Kouichi; Yamanaka, Hisashi.

In: Modern Rheumatology, Vol. 18, No. 2, 04.2008, p. 146-152.

Research output: Contribution to journalArticle

Tanaka, Yoshiya ; Takeuchi, Tsutomu ; Inoue, Eisuke ; Saito, Kazuyoshi ; Sekiguchi, Naoya ; Sato, Eri ; Nawata, Masao ; Kameda, Hideto ; Iwata, Shigeru ; Amano, Kouichi ; Yamanaka, Hisashi. / Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan : One-year clinical outcomes (RECONFIRM-2). In: Modern Rheumatology. 2008 ; Vol. 18, No. 2. pp. 146-152.
@article{151ff0b1e136462aa994c89021413ce2,
title = "Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical outcomes (RECONFIRM-2)",
abstract = "Biologics targeting TNF have brought about a paradigm shift in the treatment of rheumatoid arthritis (RA) and infliximab, anti-TNF-α chimeric monoclonal antibody, was marketed in 2003 in Japan. We previously reported on the RECONFIRM study, a retrospective clinical study on the efficacy of infliximab therapy in a RA management group in Japan, where we evaluated the clinical response after 22 weeks of the therapy in 258 patients. The study reported here was aimed at reconfirming the clinical efficacy of the infliximab therapy and demographic factors related to the efficacy over a 54-week study period in 410 RA patients in the same study group. Infliximab was infused according to the domestically approved method, and the clinical response was evaluated following 54 weeks of infliximab therapy using the European League Against Rheumatism (EULAR) response criteria. Disease activity was assessed by DAS28-CRP (Disease Activity Score including a 28-joint count/C-reactive protein). Infliximab was discontinued in 24.4{\%} of the 410 patients at 54 weeks and 9.3{\%} and 8.1{\%} discontinued the therapy due to adverse events and inefficiency, respectively. Average DAS28-CRP decreased from 5.5 at week 0 to 3.1 at week 54 after the therapy. Patients in remission and those showing low-, moderate-, and high-disease activity changed from 0.0, 1.0, 9.0 and 90.0{\%}, respectively, at the start of the study to 27.6, 11.7, 34.4 and 26.3{\%}, respectively, at week 54. Younger age, RF-negativity and low scores of DAS28-CRP showed significant correlations with remission at week 54. EULAR response criteria - good, moderate, and no response to infliximab - were 37.0, 41.7 and 21.2{\%}, respectively. In conclusion, we reconfirmed the clinical efficacy of infliximab and demographic factors related to the efficacy over a 54-week study period in 410 Japanese patients with RA using DAS28-CRP and EULAR response criteria.",
keywords = "EULAR response, Infliximab, Retrospective study, Rheumatoid arthritis",
author = "Yoshiya Tanaka and Tsutomu Takeuchi and Eisuke Inoue and Kazuyoshi Saito and Naoya Sekiguchi and Eri Sato and Masao Nawata and Hideto Kameda and Shigeru Iwata and Kouichi Amano and Hisashi Yamanaka",
year = "2008",
month = "4",
doi = "10.1007/s10165-008-0026-3",
language = "English",
volume = "18",
pages = "146--152",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan

T2 - One-year clinical outcomes (RECONFIRM-2)

AU - Tanaka, Yoshiya

AU - Takeuchi, Tsutomu

AU - Inoue, Eisuke

AU - Saito, Kazuyoshi

AU - Sekiguchi, Naoya

AU - Sato, Eri

AU - Nawata, Masao

AU - Kameda, Hideto

AU - Iwata, Shigeru

AU - Amano, Kouichi

AU - Yamanaka, Hisashi

PY - 2008/4

Y1 - 2008/4

N2 - Biologics targeting TNF have brought about a paradigm shift in the treatment of rheumatoid arthritis (RA) and infliximab, anti-TNF-α chimeric monoclonal antibody, was marketed in 2003 in Japan. We previously reported on the RECONFIRM study, a retrospective clinical study on the efficacy of infliximab therapy in a RA management group in Japan, where we evaluated the clinical response after 22 weeks of the therapy in 258 patients. The study reported here was aimed at reconfirming the clinical efficacy of the infliximab therapy and demographic factors related to the efficacy over a 54-week study period in 410 RA patients in the same study group. Infliximab was infused according to the domestically approved method, and the clinical response was evaluated following 54 weeks of infliximab therapy using the European League Against Rheumatism (EULAR) response criteria. Disease activity was assessed by DAS28-CRP (Disease Activity Score including a 28-joint count/C-reactive protein). Infliximab was discontinued in 24.4% of the 410 patients at 54 weeks and 9.3% and 8.1% discontinued the therapy due to adverse events and inefficiency, respectively. Average DAS28-CRP decreased from 5.5 at week 0 to 3.1 at week 54 after the therapy. Patients in remission and those showing low-, moderate-, and high-disease activity changed from 0.0, 1.0, 9.0 and 90.0%, respectively, at the start of the study to 27.6, 11.7, 34.4 and 26.3%, respectively, at week 54. Younger age, RF-negativity and low scores of DAS28-CRP showed significant correlations with remission at week 54. EULAR response criteria - good, moderate, and no response to infliximab - were 37.0, 41.7 and 21.2%, respectively. In conclusion, we reconfirmed the clinical efficacy of infliximab and demographic factors related to the efficacy over a 54-week study period in 410 Japanese patients with RA using DAS28-CRP and EULAR response criteria.

AB - Biologics targeting TNF have brought about a paradigm shift in the treatment of rheumatoid arthritis (RA) and infliximab, anti-TNF-α chimeric monoclonal antibody, was marketed in 2003 in Japan. We previously reported on the RECONFIRM study, a retrospective clinical study on the efficacy of infliximab therapy in a RA management group in Japan, where we evaluated the clinical response after 22 weeks of the therapy in 258 patients. The study reported here was aimed at reconfirming the clinical efficacy of the infliximab therapy and demographic factors related to the efficacy over a 54-week study period in 410 RA patients in the same study group. Infliximab was infused according to the domestically approved method, and the clinical response was evaluated following 54 weeks of infliximab therapy using the European League Against Rheumatism (EULAR) response criteria. Disease activity was assessed by DAS28-CRP (Disease Activity Score including a 28-joint count/C-reactive protein). Infliximab was discontinued in 24.4% of the 410 patients at 54 weeks and 9.3% and 8.1% discontinued the therapy due to adverse events and inefficiency, respectively. Average DAS28-CRP decreased from 5.5 at week 0 to 3.1 at week 54 after the therapy. Patients in remission and those showing low-, moderate-, and high-disease activity changed from 0.0, 1.0, 9.0 and 90.0%, respectively, at the start of the study to 27.6, 11.7, 34.4 and 26.3%, respectively, at week 54. Younger age, RF-negativity and low scores of DAS28-CRP showed significant correlations with remission at week 54. EULAR response criteria - good, moderate, and no response to infliximab - were 37.0, 41.7 and 21.2%, respectively. In conclusion, we reconfirmed the clinical efficacy of infliximab and demographic factors related to the efficacy over a 54-week study period in 410 Japanese patients with RA using DAS28-CRP and EULAR response criteria.

KW - EULAR response

KW - Infliximab

KW - Retrospective study

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=41849132452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849132452&partnerID=8YFLogxK

U2 - 10.1007/s10165-008-0026-3

DO - 10.1007/s10165-008-0026-3

M3 - Article

VL - 18

SP - 146

EP - 152

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 2

ER -